Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BHC Company was a landmark joint venture between the Boots Company and Hoechst Celanese Corporation, established in the mid-1980s to innovate the industrial synthesis of ibuprofen. The company is renowned for developing the "BHC Ibuprofen Process," a three-step catalytic method that revolutionized bulk pharmaceutical manufacturing by significantly improving atom economy and reducing environmental waste. This "green chemistry" breakthrough was commercialized in 1992 at the company's facility in Bishop, Texas, and received the inaugural Presidential Green Chemistry Challenge Award in 1997. The process replaced the traditional six-step Boots method, doubling the atom efficiency and virtually eliminating hazardous waste byproducts. The BHC ibuprofen business was eventually acquired by BASF Corporation, which continues to operate the Bishop plant as one of the world's largest ibuprofen production sites.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BHC Ibuprofen.